Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2023—The Association for Diagnostics and Laboratory Medicine (formerly AACC) and the American Diabetes Association last month issued guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (Sacks DB, et al. Clin Chem. 2023;69[8]:808–868).
July 2023—LGC Clinical Diagnostics has launched the SeraCare Accurun MS2, a full-process internal control that can be used as a tool to monitor the process integrity of sample extraction and amplification of nucleic acid amplification–based assays. The product contains positive materials of intact MS2 bacteriophage, and the ready-to-use controls can be spiked into specimens that are going through DNA/RNA extraction.
July 2023—Randox (Crumlin, U.K.) has acquired Cellix, a Dublin-based company that develops microfluidic tools and impedance flow cytometers for cell analysis.
July 2023—General Data Healthcare’s Flex is the latest addition to its LaserTrack portfolio of cassette printers.
July 2023—BD announced the worldwide commercial launch of its BD FacsDuet Premium system. The automated instrument prepares samples for in vitro diagnostic and user-defined tests, including cocktailing, washing, and centrifuging, and then automatically transfers samples to the integrated BD FacsLyric clinical flow cytometry system, enabling a walkaway workflow solution.
July 2023—Verichem Laboratories now offers its customers free access to its Web-based and online calibration verification data reduction and test-reporting programs. Designed for use with the company’s clinical reference materials, these programs and services provide the necessary statistical data and test reports to satisfy CLIA requirements for the calibration verification of clinical assays. Users can register online with a password, log in, and then enter and submit data; there is no software to download. Reports are generated instantly in a PDF format and are ready to review, sign off, and file. Final reports can include clinical system test accuracy, linearity, precision, precision with peer comparison, and other supplemental study data. Technical support is available via phone to answer questions or troubleshoot.
July 2023—Bio-Rad Laboratories launched two Exact Diagnostics products, Bulk Urine Negative and Bulk CSF Negative controls. The bulk urine negative control is intended to be validated as an independent external quality run control to monitor the absence of adenovirus, BK virus, Candida auris, Chlamydia trachomatis, cytomegalovirus, John Cunningham virus, Mycoplasma genitalium, Neisseria gonorrhoeae, Trichomonas vaginalis, and Zika virus in various molecular assays. The bulk CSF negative control is an independent external quality run control intended to monitor the absence of Anaplasma phagocytophilum, Babesia microti, Bartonella quintana, Borrelia burgdorferi, Ehrlichia chaffeensis, enterovirus, herpes simplex virus 1 and 2, and varicella-zoster virus in various molecular assays.
July 2023—Siemens Healthineers has entered into an agreement with Scopio Labs to distribute the Scopio X100 and Scopio X100HT. These imaging platforms will complement Siemens hematology systems, including the Atellica Hema 570 and Hema 580 analyzers, to offer laboratories high-resolution, full-field viewing for peripheral blood specimens and artificial intelligence–based morphological analysis with remote viewing capabilities.
July 2023—OGT, a Sysmex Group company, announced a commercial partnership with Applied Spectral Imaging. The agreement will grant OGT rights to market ASI’s proprietary cytogenetic imaging and analysis solutions in Great Britain, establishing a strategic partnership that the companies say combines the strengths of OGT’s CytoCell FISH portfolio with ASI’s imaging and analysis capabilities.
July 2023—Qiagen announced that its variant interpretation and reporting software, Qiagen Clinical Insight (QCI) Interpret, was chosen by the Danish National Genome Center to provide interpretation of oncology results generated from whole genome sequencing data. The initiative is part of a larger personalized medicine strategy that aims to provide WGS as the standard of care for relevant patient groups throughout Denmark.
